Phase 4Active, not recruiting
DUTCH Weight Control in Atrial Fibrillation Study (DUTCH-WAIST)
DUTCH Weight Control in Atrial Fibrillation Study, a Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Trial
- Sponsor
- Rijnstate Hospital (Academic or other)
- Enrolment
- 280 planned
- Conditions
- Atrial Fibrillation; Obesity; Weight Loss
- Interventions
- Semaglutide 3.2 MG/ML; Placebo
- Ages
- adults, older adults
- Registry
- NCT06184633
Full record on ClinicalTrials.gov
From the registry
Quantify the effect of an innovative weight loss management on rhythm control.
Primary outcomes
- The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered
In the news
ResearchDeutsches Ärzteblatt (opens Deutsches Ärzteblatt in a new tab)
Researchers find weight loss cannot fully explain semaglutide’s 20% cardiovascular risk reduction
The SELECT mediation analysis examined 24-month risk-factor changes in adults with cardiovascular disease, BMI ≥27 and no diabetes, assigned to weekly semaglutide targeting 2.4 mg or placebo.
